Clicky

Foghorn Therapeutics Inc.(FHTX) News

Date Title
May 14 Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
May 7 Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development
May 5 Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
Apr 28 Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
Oct 3 Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
Oct 1 Foghorn Therapeutics to Participate in the BMO Oncology Summit
Jul 29 Institutional investors own a significant stake of 36% in Foghorn Therapeutics Inc. (NASDAQ:FHTX)
May 9 Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 7 Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 6 Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
May 6 Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
May 6 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Apr 16 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Apr 9 Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Apr 9 Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Apr 5 Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Apr 2 Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
Mar 26 Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Mar 13 Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
Mar 13 Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know